JNJ vs VST: Which Is the Better Buy?

Side-by-side comparison of Johnson & Johnson and Vistra Corp. β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-09-25.
Johnson & Johnson Β· Healthcare
$270.68
+5.7% upside to fair value
Med Conviction Grade C High Quality
VS
Vistra Corp. Β· Utilities
$140.67
-23.0% upside to fair value
Med Conviction Grade C
QuantHub Verdict
JNJ has more upside to fair value (+5.7%). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric JNJ VST
Current Price $270.68 $140.67
Fair Value Estimate $286.05 $108.27
Upside to Fair Value +5.7% -23.0%
Market Cap $652.3B $47.4B
Forward P/E β€” β€”
EV / EBITDA 20.2x 10.3x
Price / Sales 6.7x 3.0x
Price / FCF 35.3x 34.7x
Revenue Growth YoY +6.6% -5.5%
Gross Margin 67.9% 13.0%
Operating Margin 26.8% 2.3%
Return on Equity 25.7% 41.5%
Dividend Yield 1.95% 0.65%
FCF Yield 2.83% 2.88%
Analyst Consensus Buy Strong Buy
Investment Thesis
JNJ β€” Johnson & Johnson
Johnson & Johnson is a 141,700-employee healthcare holding company operating two segments, Innovative Medicine (immunology, oncology, neuroscience, infectious disease, cardiovascular and metabolism, pulmonary hypertension) and MedTech (interventional solutions, orthopaedics, surgery, vision), founded in 1887 and headquartered in New Brunswick, New Jersey. Business quality is high on fundamentals:…
VST β€” Vistra Corp.
Vistra Corp. is a vertically integrated independent power producer and retail electricity supplier operating roughly 38,700 megawatts of generation across natural gas, nuclear, coal, solar, and battery storage, serving about 4.3 million retail customers in 20 states and the District of Columbia. The business quality is mixed: the diversified PJM and ERCOT fleet plus retail load is a genuine struc…
Accumulation Zones
Metric JNJ VST
Zone Low $214.54 $81.20
Zone High $243.14 $92.03
In Buy Zone? No No
← JNJ Research    VST Research β†’    All Research